Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): A brief review

Keyun Tang1,2 | Yuanzhuo Wang1,2 | Hanlin Zhang1,2 | Qingyue Zheng1,2 | Rouyu Fang1 | Qiuning Sun1

1Department of Dermatology, Peking Union Medical College Hospital, Beijing, China
2Eight-year MD Program, Peking Union Medical College, Beijing, China

Correspondence
Qiuning Sun, Department of Dermatology, Peking Union Medical College Hospital, No. 1, Shuaifuyuan, Dongcheng District, Beijing, China.
Email: doctorjenny1@163.com

Abstract
COVID-19, first appeared in December 2019 in Wuhan, China, has been spreading quickly throughout the world. We reviewed the evidence on cutaneous manifestations of COVID-19 based on PubMed database. The searching strategy was (COVID* or coronavirus*) and (dermatol* or skin* or cutaneous*). The publication time was limited to 2019 onward. After independent review by two authors, 14 studies with 228 confirmed cases were included in the analysis. A total of 60 patients developed skin rashes, and the age ranged from 8 to 84. Exanthematous eruptions potentially related to COVID-19 infection were highly variable and heterogeneous. Skin lesions mainly appeared erythematous, urticarial, and vesicular (chicken pox-like or varicelliform). Petechiae rash, livedo reticularis, and reactivation of oral HSV-1 were also observed in single cases. Newly reported eruptions like vascular lesions and peculiar (perniosis-like) skin lesions caused concern among dermatologists. Exanthems were widely distributed and were primarily located on the trunk. Associated symptoms, latency time, treatment, and prognosis were also carefully summarized. This study reviewed the recently published COVID-19 studies with skin manifestations, which may pave the way for further research.

KEYWORDS
coronavirus, COVID-19, cutaneous manifestations, review, skin

1 | INTRODUCTION

Coronavirus Disease 2019 (COVID-19) has been spreading quickly throughout the world since its first appearance in December 2019 in Wuhan, China. World Health Organization (WHO) declared a pandemic condition in March, with the confirmed case number gradually rising to 2,626,321 globally by April 25th, 2020. Common clinical features of this virus infection inside and outside of the respiratory system include fever, cough, headache, diarrhea, fatigue, headache, and myalgia.1 Dermatological symptoms are reported sporadically, and the roles of skin lesions in early recognition and disease progression have not been extensively studied. In this short review, we will present evidence on cutaneous manifestations and relevant implications in the context of COVID-19, which may highlight dermatological aspects and help dermatologists understand the disease.

2 | METHODS

The literature search using the following search strategy was conducted on Pubmed database on April 25th, 2020 to identify eligible articles: (COVID* or coronavirus*) and (dermatol* or skin* or cutaneous*). The publication time was limited to 2019 onward. A total of 170 papers were identified by the initial search. Two reviewers independently reviewed the abstracts and full-texts. Reports on the range
of cutaneous manifestations associated with COVID-19 were included in this review.

3 | RESULTS

Overall, 16 studies with 256 confirmed COVID-19 cases were included in the final analysis. A total of 88 patients developed skin rashes, and the age ranged from 8 to 84. Of the 50 patients with determined gender, 27 (54%) were males and 23 (46%) were females. The only prospective study showed that 5 (4.9%) patients in France presented with cutaneous manifestations associated with infections, which was lower than the rate of occurrences of skin rashes in a previous retrospective study (20.4%, 18 out of 88; Table 1).3

Exanthematous eruptions potentially related to COVID-19 infection were highly variable. Skin lesions mainly appeared erythematous, urticarial, and vesicular (chicken pox-like or varicelliform).1–12 Periostitis rash,13 livedo reticularis,14 and reactivation of oral herpes simplex virus type 1 (HSV-1)2 were also observed in single cases. Newly reported eruptions like vascular lesions and peculiar (perniosis-like) skin lesions caused concern among dermatologists.15,16 Exanthems were widely distributed and were primarily located on the trunk. Patients often presented with other clinical symptoms during the disease course, including fever, cough, headache, weakness, coryza, dyspnea, and other respiratory problems.1,5–7,14 The latency time from systemic symptoms to exanthem ranged from −2 to 21 days, and lesions of three patients were detected during the prodromal or subclinical phase.1,8,11 Thirteen patients remained asymptomatic across the entire observation period except for peculiar lesions, red-purple papules, and additional erythematous.4,16

Of the nine patients receiving medications, four patients received conservative drug therapy for exanthem.1,5,6,9 Oral antihistamines contributed to clinical and symptomatic improvement in two patients with urticaria.1,6 Local corticosteroids were given to a patient with erythematous-yellowish papules, however, these papules progressed into hardened and pruritic erythematous plaque 3 days later despite the treatment.5 Another patient with confluent erythematous patches and worsening dermatitis demonstrated a good response to triamcinolone 0.1% cream.9 These agents were used in combination with systemic drugs for infectious complications and symptoms. Five patients receiving treatment for symptoms of COVID-19 infection had no specific agents for skin rashes. Based on the recorded clinical outcomes in four of five patients, rash improved or disappeared within a few days spontaneously.10,11 Among nine patients receiving treatments,1,5,7,9–11 two presented with rash before1,11 while six developed skin eruptions following drug administration.5,7,10,11

4 | DISCUSSION

Recently, Recalcati and colleagues reported the cutaneous manifestations of COVID-19 infection in Italy and asked for more papers to confirm and better understand the pattern of skin involvement with COVID-19.3 As the disease became pandemic globally, additional evidence has been constantly emerging. Therefore, we conducted a study to briefly review the ongoing research advances.

For COVID-19 treatment, one possible treatment option was the combination of anti-viral medicine (hydroxychloroquine and lopinavir/ritonavir) with antibiotics (azithromycin, levofloxacin, and ceftriaxone). Supporting therapy of paracetamol or benzonatate could also be performed. However, only four case reports mentioned medicine usage for skin symptoms, including oral antihistamines and local corticosteroids.1,5,6,9 Antihistamines and corticosteroids are commonly used as anti-inflammation and anti-allergic agents, but they will increase the risk of infection as well. This paradox may restrict the usage of these medicines, especially in COVID-19 patients. Policies and guidelines for the treatment of COVID-19 were different among countries, and some researchers refused to give any treatments for asymptotic patients or those with mild symptoms because the symptoms may spontaneously remiss after several days.

The pathogenesis of cutaneous manifestations remains unknown and may be extremely different among these researches. Mottling, livedo reticularis, petechial rash, purpura, chilblastin, and other vascular signs could be associated with a series of thrombotic events such as disseminated intravascular coagulation (DIC), hyaline thrombus formation, acral ischemia, and thrombocytopenia.4,14,15 Immune dysregulation, vasculitis or neangiogenesis might also be associated with lesions’ pathophysiology.15 In other cases, skin rash may be directly induced by virus infection as is common in other viral diseases, for example, dengue, rubella, and measles. However, differential diagnosis of exanthematous eruption is problematic since drug eruptions and viral exanthems share considerable similarities.10 Recalcati preliminarily excluded the skin lesion from the usage of a novel drug by analyzing the medication history of patients.3 Raffaele Gianotti provided histopathological evidence by biopsy, finding viral particles in the cutaneous blood vessels in patients with COVID-19 infection.11 Recently, Recalcati raised a hypothesis that peculiar lesions that were unreported in previous literature may represent late clinical manifestations of COVID-19 infection among young healthy individuals. To clarify the underlying mechanisms, large-scale prospective studies with biopsies, serological tests showing antibody response to virus infection and PCR analysis of suspected patients are warranted. Since the time kinetics of skin exanthem and viremia probably vary among different infections, it may be significant to measure blood viral load at different time points (before, during, or after lesions onset), thereby determine the appropriate time of biopsies for molecular identification.

Several effective measures have been taken in hospitals across China to control the spread of COVID-19 and ensure public health. Services of dermatology outpatient department and surgery in Peking Union Medical College were postponed where only emergency operations were conducted. Meanwhile, to meet the patients’ medical requirements and to reduce the capacity of skin clinics, we provided follow-ups and free dermatological consultations through telephone and social media, particularly for patients with severe autoimmune diseases and those receiving biologics and chemotherapeutics. We
| Author and year | Study design | Number of patients | Age and gender | Coronavirus diseases 2019 manifestations | Treatment for Coronavirus diseases 2019 | Skin manifestation | Days after the onset of Coronavirus diseases 2019 symptoms | Location of the skin symptoms | Treatment for dermatology symptoms | Clinical outcome of the skin manifestation |
|-----------------|--------------|--------------------|----------------|------------------------------------------|-------------------------------------|-------------------|-----------------------------------------------|-------------------------------|-----------------------------------|---------------------------------------------|
| Fernandez-Nieto and colleagues, 2020 | Retrospective, case report | 1 | 32, female | Unavailable | Hydroxychloroquine and azithromycin | Urticariform | 6 | Unavailable | Oral antihistamines | Clinical and symptomatic improvement |
| Anwar Alramthan and colleagues, 2020 | Retrospective, case series | 2 | 27, female; 35, female | Asymptomatic | None | Red-purple papules and additional erythematous macules | Unavailable | Dorsal aspect of fingers bilaterally | Unavailable | Unavailable |
| Andrea Estébanez and colleagues, 2020 | Retrospective, case report | 1 | 28, female | Dry cough, nasal congestion, fatigue, myalgias, and arthralgias without fever | Paracetamol for 4 d | First pruritic lesions and then confluent erythematous-yellowish papules | 14 | Both heels | Local corticosteroids | Lesions persisted and became erythematous plaques that both hardened and became pruritic |
| Diane Henley and colleagues, 2020 | Retrospective, case report | 1 | 27, female | Odynophagia but chills, chest pain, fever, moderate lymphopenia, rise of C reactive protein after 2 d | Paracetamol | Diffuse arthralgia and puritic disseminated erythematous plaques eruption, confirmed with urticaria | 2 d before | Particular face and acral involvement | Antihistamines | Slow improvement |
| Brey Jodi and colleagues, 2020 | Retrospective, case report | 1 | Unavailable | Low platelet count, respiratory problems | Unavailable | Petechiae rash | Unavailable | Unavailable | Unavailable | Unavailable |
| Juan Jimenez-Cashe and colleagues, 2020 | Retrospective, case report | 1 | 84, female | Bilateral pneumonia | Hydroxychloroquine and lopinavir/ritonavir | Erythematous macules; exanthem; pruritic eruption of erythematous macules and papules | 11 | Flexural regions, mildly pruriginous and mainly located in the peri-axillary area | Unavailable | Unavailable |
| Giovanni Genovese and colleagues, 2020 | Retrospective, case report | 1 | 8, female | Fever, mild cough, and thrombocytopenia | None | Forty erythematous papules and few vesicles scattered, resembling varicella-like exanthem | 6 | Bilaterally and symmetrically on the trunk | None | Subsided in 7 d |
| Raffaele Gianotti and colleagues, 2020 | Retrospective, case series | 3 | 59, female; 89, female; 57, male | Fever and cough | Lopinavir-ritonavir, heparin and levofloxacin; ceftriaxone and azithromycin; levofloxacin; and hydroxychloroquine | Erythematous macules; exanthem; pruritic eruption of erythematous macules and papules | 3-7 d before | Arms, trunk and lower limbs, trunk and arms | None | Spontaneously improved |
| Antoine Mahe and colleagues, 2020 | Retrospective, case report | 1 | 64, female | Fever, asthenia, and cough | Oral paracetamol | Erythematous rash | 4 | First both antecubital fossa, then extended to the trunk and axillary folds | None | Rash disappeared 5 d after its beginning |
| Ivanescan F. Manalo and colleagues, 2020 | Retrospective, case report | 2 | 67, male; 47, male | Fever, nasal congestion, postnasal drip, and cough; gross hematuria and generalized weakness, a mild headache; sinus pressure, anemia, and fever | Unavailable | Nonpruritic blanching unilateral livedoid patches; unilateral asymptomatic rash, resembling livedo reticulans | 7-10 | Right anterior thigh | Unavailable | Resolved or disappeared |
| Marzano and colleagues, 2020 | Retrospective, observational study | 22 | Median age of 60. 72.7% male | Most observed with fever (95.8%) cough (72.7%), headache (90%), weakness (50%), myalgia (45.8%), dyspnea (40.9%) and other symptoms | Unavailable | Varicella-like papulovesicular exanthem and mille/ absent pruritus | 3 d of median (range from −2 to 12 d) | Scattered in most cases (72.7%) and diffuse in 6 cases (27.3%); constant trunk involvement | Unavailable | Unavailable |

(Continues)
| Author and year | Study design | Number of patients | Age and gender | Coronavirus diseases 2019 manifestations | Treatment for Coronavirus diseases 2019 | Skin manifestation | Days after the onset of Coronavirus disease 2019 symptoms | Location of the skin symptoms | Treatment for dermatology symptoms | Clinical outcome of the skin manifestation |
|-----------------|--------------|--------------------|----------------|------------------------------------------|-----------------------------------------|-------------------|-------------------------------------------------|---------------------------------|-----------------------------------|---------------------------------------|
| Sebastiano Recalcati and colleagues, 2020 | Retrospective, observational study | 18 out of 88 | Unavailable | Unavailable | Erythematous rash (77.7%), widespread urticaria (16.6%) and chickenpox-like vesicles (5.6%) | Unavailable | 44.4% developed at the onset and 55.6% after the hospitalization | Trunk mostly involved | Unavailable | Remission of itching and healing of lesions in a few days |
| David J. Najarian and colleagues, 2020 | Retrospective, case report | 1 | 58, male | Cough, pain in hands, and lower extremities | Azithromycin and benzonatate | Pruritic, expanding, and worsening dermatitis, erythematous macules, confirmed with viral DNA or RNA shed | Unavailable | Widespread, on the legs, thighs, forearms, arms, shoulders, back, chest, and abdomen | Triamcinolone | Improvement of the dermatitis |
| Hedou M. and colleagues, 2020 | Prospective, pilot study | 5 out of 103 | Unavailable | Unavailable | Erythematous rash (40%), urticaria (40%) and an oral herpes simplex virus type 1 (HSV-1) reactivation (20%) | Unavailable |主要位于面部和上半身 | Unavailable | Disappeared with a median time of 48 h (from 24 h to 6 d) |
| Sebastiano Recalcati and colleagues, 2020 | Retrospective, case series | 14 | 11 children (average age 14.4 y, range 13-18) and 3 young adults (average age 29 y, range 23-39), female–male was 8:6 | Asymptomatic (n = 11), cough and fever (n = 3) | Unavailable | Peculiar (papilloma-like): acral eruption of erythematous-violaceous papules and macules, with possible bullous evolution, or digital swelling | 3 wk before (n = 3) | Located on the feet in 8 cases, on the hands in 4 cases, on both sites in 2 | None | Developed into erythematous-violaceous papules and macules in two children; resolved after 2 to 4 w without treatment |
| Jean David Bouaziz and colleagues, 2020 | Retrospective, observational study | 14 | Unavailable | Respiratory distress, chest pain and cough, fever, anosmia | Unavailable | Inflammatory lesions: exanthema (n = 4), chicken pox like vesicles (n = 2), cold urticaria (n = 2); Vascular lesions: violaceous macules with “porcelain-like” appearance (n = 1), livido (n = 1), non-necrotic purpura (n = 2), necrotic purpura (n = 1); children appearance with Raynaud’s phenomenon (n = 1), eruptive cherry angioma (n = 1) | Few days after systemic symptoms onset | Unavailable | Unavailable | Unavailable |
| Fernandez-Nieto D and colleagues, 2020 | Retrospective, case report | 1 | 32, female | Unavailable | Hydroxychloroquine and azithromycin | Urticarinform | 6 | Unavailable | Oral antihistamines | Clinical and symptomatic improvement |
| Anwar Alramthan and colleagues, 2020 | Retrospective, case series | 2 | 27, female; 35, female | Asymptotic | None | Red-purple papules and additional erythematous | Unavailable | Dorsal aspect of fingers bilaterally | Unavailable | Unavailable |
| Andrea Estebanez and colleagues, 2020 | Retrospective, case report | 1 | 28, female | Dry cough, nasal congestion, fatigue, myalgia, and arthralgias without fever | Paracetamol for 4 d | First pruritic lesions and then confluent erythematous-yellowish papules | 14 | Both heels | Local corticosteroids | Lesions persisted and became erythematous plaques that both hardened and became pruritic |
| Author and year                  | Study design                  | Number of patients | Age and gender | Coronavirus diseases 2019 manifestations | Treatment for Coronavirus diseases 2019 | Skin manifestation                                                                 | Days after the onset of Coronavirus diseases 2019 symptoms | Location of the skin symptoms                  | Treatment for dermatology symptoms | Clinical outcome of the skin manifestation |
|---------------------------------|-------------------------------|--------------------|----------------|------------------------------------------|----------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------|-------------------------------------|----------------------------------------|
| Diane Henry and colleagues, 2020| Retrospective, case report    | 1                  | 27, female     | Odynophagia but chills, chest pain, fever, moderate lymphopenia, rise of C reactive protein after 2 d | Paracetamol                            | Diffuse arthralgia and pruritic disseminated erythematosus plaques eruptions, confirmed with urtica | 2 d before                                          | Particular face and acral involvement         | Antihistamines                         | Slow improvement                        |
| Beuy Joob and colleagues, 2020  | Retrospective, case report    | 1                  | Unavailable    | Low platelet count, respiratory problems | Paracetamol                            | Unavailable                                                                        | 2 d before                                          | Unavailable                              | Unavailable                          | Unavailable                           |
| Juan Jimenez-Cueto and colleagues, 2020 | Retrospective, case report | 1                  | 84, female     | Bilateral pneumonia                      | Hydroxychloroquine and lopinavir/ritonavir | Erythematous-purpuric, millimetric, coalescing macules                            | 11                                                   | Unavailable                              | Unavailable                          | Unavailable                           |
| Giovanni Genovese and colleagues, 2020 | Retrospective, case report     | 1                  | 8, female      | Fever, mild cough, thrombocytopenia      | Lopinavir-ritonavir                     | Forty erythematous papules and few vesicles scattered, resembling varicella-like exanthem | 6                                                   | Bilaterally and symmetrically on the trunk | Unavailable                          | Subsided in 7 d                        |
| Raffaele Giorgetti and colleagues, 2020 | Retrospective, case series   | 3                  | 59, female; 89, female; 57, male       | Fever and cough                         | Lopinavir-ritonavir, heparin and levofloxacin; levofloxacin and hydroxychloroquine | Erythematous macules: exanthem, pruritic eruption of erythematous macules and papules | 3;7;2 d before                                     | Unavailable                              | Unavailable                          | Spontaneously improved                  |
| Antoine Mehe and colleagues, 2020 | Retrospective, case report    | 1                  | 64, female     | Fever, asthenia, cough                   | Oral paracetamol                       | Erythematous rash                                                                  | 4                                                   | Unavailable                              | None                                | Resolved or disappeared                 |
| Iviensan F. Manalo and colleagues, 2020 | Retrospective, case report | 2                  | 67, male; 47, male | Fever, nasal congestion, prostrudal drip and cough, gross hematuria and generalized weakness, a mild headache, sinus pressure, anemia and fever | None                                   | Nonpruritic blanching unilateral livedoid patch; unilateral asymptomatic rash, resembling livedo reticularis | 7;10                                               | Right anterior thigh                    | Unavailable                          | Resolved or disappeared                 |
| Marzano and colleagues, 2020     | Retrospective, observational study | 22                 | Median age of 60, 72.7% male            | Most observed with fever (95.5%), cough (72.7%), headache (50%), weakness (50%), coryza (45.5%), dyspnea (40.9%), and other symptoms | Unavailable                            | Varicella-like papulosquamous exanthem and miliary/pruritic rash                  | 3 d of median (range from ~2 to 12 d)             | Scattered in most cases (72.7%) and diffuse in 6 cases (27.3%) constant trunk involvement | Unavailable                          | Unavailable                           |
| Sebastiano Recalcati and colleagues, 2020 | Retrospective, observational study | 18 out of 88       | Unavailable    | Unavailable                              | Unavailable                            | Erythematous rash (77.7%), widespread urtica (16.6%) and chilamopox-like vesicles (5.6%) | 44.4% developed at the onset and 55.6% after the hospitalization | Trunk mostly involved                    | Unavailable                          | Remission of itching and healing of lesions in a few days |
| David J. Najarian and colleagues, 2020 | Retrospective, case report    | 1                  | 58, male       | Cough, pain in hands and lower extremities | Azithromycin and benzonatate           | Pruritic, expanding, and worsening dermatitis, erythematous macules, confirmed with morbilliform exanthem | Unavailable                                         | Unavailable                              | Triamcinolone                         | Improvement of the dermatitis          |
| Author and year                  | Study design          | Number of patients | Age and gender | Coronavirus diseases 2019 manifestations | Treatment for Coronavirus diseases 2019 | Skin manifestation                                                                 | Days after the onset of Coronavirus disease 2019 symptoms | Location of the skin symptoms | Treatment for dermatology symptoms | Clinical outcome of the skin manifestation |
|---------------------------------|-----------------------|--------------------|----------------|------------------------------------------|----------------------------------------|------------------------------------------------------------------------------------|----------------------------------------------------------|------------------------------|-------------------------------------|------------------------------------------|
| Hedou M. and colleagues, 2020   | Prospective, pilot study | 5 out of 103       | Unavailable    | Erythematous rash (40%), urtica (40%) and oral herpes simplex virus type 1 (HSV-1) reactivation (20%) | Unavailable                           | Unavailable                                                                                   | unavailable                                      | Mainly located on the face and the upper body | None                                                | Disappeared with a median time of 48 h (from 24 h to 6 d) |
| Sebastiano Recalcati and colleagues, 2020 | Retrospective, case series | 14                 | 11 children (average age 14.4 y, range 13–38) and 3 young adults (average age 29 y, range 23–39), female-male was 8:6 | Asymptomatic (n = 13), cough and fever (n = 3) | Unavailable                           | Peculiar (perniosis-like): acral eruption of erythematous-violaceous papules and macules, with possible bulla evolution, or digital swelling | 3 w before (n = 3)                             | Located on the feet in 8 cases, on the hands in 4 cases, on both sites in 2 | None                                                | Developed into erythematous-papular targetoid lesions in 2 children, resolved after 2 to 4 w without treatment |
| Jean David Bouaziz and colleagues, 2020 | Retrospective, observational study | 14                 | Unavailable    | Respiratory distress, chest pain and cough, fever, anosmia | Unavailable                           | Inflammatory lesions: exanthema (n = 4), chicken pox-like vesicles (n = 2), cold urtica (n = 1), Vascular lesions: violaceous macules with “porcelain-like” appearance (n = 1), livedo (n = 1), non-necrotic purpura (n = 1), necrotic purpura (n = 1), chilblain appearance with Raynaud’s phenomenon (n = 1), eruptive cherry angioma (n = 1) | Few days after systemic symptoms onset             | Unavailable                                      | Unavailable                                                | Unavailable                                                |
also conveyed medical knowledge about personal protection, skincare, mental health, and household cleaning to dermatological patients.

A limitation of our research is that we cannot analyze the cutaneous manifestations and disease courses quantitatively due to the relatively large amounts of unavailable and incomparable data. Close attention should be paid to the cutaneous manifestations of COVID-19 in further clinical practice. Some of them may emerge before the onset of COVID manifestations. This may be useful to identify patients or asymptomatic carriers in the risk population. Understanding how COVID-19 present on the skin may help practitioners and patients to recognize and manage the disease. In conclusion, we reviewed the recently published COVID-19 studies with cutaneous manifestations, which may pave the way for further research.

CONFLICT OF INTEREST
The authors have no conflict of interest to declare.

AUTHOR CONTRIBUTIONS
All authors contributed to the manuscript. Keyun Tang and Yuanzhuo Wang conducted the literature search and wrote the manuscript. Hanlin Zhang and Qingyue Zheng made the table. Rouyu Fang examined and collected the data. Qiuning Sun designed the study, made the analysis and examined the data. The manuscript has been read and approved by all the authors. We have thoroughly read the instructions for authors. The requirements for authorship have been met and each author believes that the manuscript represents honest work.

ORCID
Hanlin Zhang https://orcid.org/0000-0001-5065-4086
Rouyu Fang https://orcid.org/0000-0002-9224-8163
Qiuning Sun https://orcid.org/0000-0002-1912-341X

REFERENCES
1. Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol: JEADV. 2020. https://doi.org/10.1111/jdv.16472 [Epub ahead of print].
2. Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave-Roblot F, Masson Regnault M. Comment on “cutaneous manifestations in COVID-19: a first perspective” by Recalcati S. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16519 [Epub ahead of print].
3. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol: JEADV. 2020. https://doi.org/10.1111/jdv.16387 [Epub ahead of print].
4. Alramthan A, Aldaraji W. A Case of COVID-19 Presenting in Clinical Picture Resembling Chilblains Disease. First report from the Middle East. Clin Exp Dermatol. 2020. https://doi.org/10.1111/ced.14243 [Epub ahead of print].
5. Estebanez A, Perez-Santiago L, Silva E, et al. Cutaneous manifestations in COVID-19: a new contribution. J Eur Acad Dermatol Venereol: JEADV. 2020. https://doi.org/10.1111/jdv.16474 [Epub ahead of print].
6. Fernandez-Nieto D, Ortega-Quijano D, Segurado-Miravalles G, et al. Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies. J Eur Acad Dermatol Venereol: JEADV. 2020. https://doi.org/10.1111/jdv.16470 [Epub ahead of print].
7. Jimenez-Cauhe J, Ortega-Quijano D, Prieto-Barrios M, Moreno-Arrones OM, Fernandez-Nieto D. Reply to "COVID-19 can present with a rash and be mistaken for dengue": petechial rash in a patient with COVID-19 infection. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.04.016 [Epub ahead of print].
8. Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.04.044 [Epub ahead of print].
9. Najarian DJ. Morbilliform Exanthem associated with COVID-19. JAAD Case Rep. 2020. https://doi.org/10.1016/j.jrdr.2020.04.015 [Epub ahead of print].
10. Mahe A, Birckel E, Krieger S, et al. A distinctive skin rash associated with coronavirus disease 2019 ? J Eur Acad Dermatol Venereol: JEADV. 2020. https://doi.org/10.1111/jdv.16471 [Epub ahead of print].
11. Gianotti R, Veraldi S, Recalcati S, et al. Cutaneous Clinico-pathological findings in three COVID-19-positive patients observed in the metropolitan area of Milan, Italy. Acta Derm Venereol. 2020;100(8):16470-16474. https://doi.org/10.1111/actd.14201 [Epub ahead of print].
12. Genovese G, Colonna C, Marzano AV. Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: a diagnostic clue? Pediatr Dermatol. 2020. https://doi.org/10.1111/pde.14201 [Epub ahead of print].
13. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue”. J Am Acad Dermatol. 2020;82:e177.
14. Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation in COVID-19 infection. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.04.016 [Epub ahead of print].
15. Bouaziz JD, Duong T, Jachiet M, et al. Vascular skin symptoms in COVID-19: a french observational study. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16544 [Epub ahead of print].
16. Recalcati S, Barbagallo T, Frasin LA, et al. Acral cutaneous lesions in the time of COVID-19. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16533 [Epub ahead of print].

How to cite this article: Tang K, Wang Y, Zhang H, Zheng Q, Fang R, Sun Q. Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): A brief review. Dermatologic Therapy. 2020;33:e13528. https://doi.org/10.1111/dth.13528